Summit Global Investments Buys 2,195 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Summit Global Investments lifted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 22.7% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 11,868 shares of the biopharmaceutical company's stock after buying an additional 2,195 shares during the quarter. Regeneron Pharmaceuticals comprises 0.8% of Summit Global Investments' holdings, making the stock its 27th biggest position. Summit Global Investments' holdings in Regeneron Pharmaceuticals were worth $12,476,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its stake in Regeneron Pharmaceuticals by 1.0% in the first quarter. Vanguard Group Inc. now owns 8,930,241 shares of the biopharmaceutical company's stock valued at $8,595,268,000 after buying an additional 91,956 shares during the period. Capital International Investors grew its position in Regeneron Pharmaceuticals by 7.3% in the 1st quarter. Capital International Investors now owns 3,129,010 shares of the biopharmaceutical company's stock valued at $3,011,640,000 after purchasing an additional 213,038 shares during the period. Price T Rowe Associates Inc. MD increased its stake in Regeneron Pharmaceuticals by 25.7% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 902,613 shares of the biopharmaceutical company's stock valued at $868,757,000 after purchasing an additional 184,561 shares in the last quarter. International Assets Investment Management LLC raised its holdings in Regeneron Pharmaceuticals by 86,013.3% during the third quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company's stock worth $926,078,000 after buying an additional 879,916 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA lifted its position in Regeneron Pharmaceuticals by 12.4% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 540,293 shares of the biopharmaceutical company's stock valued at $567,864,000 after acquiring an additional 59,769 shares in the last quarter. Institutional investors own 83.31% of the company's stock.

Insider Transactions at Regeneron Pharmaceuticals

In related news, CFO Christopher R. Fenimore sold 5,680 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the sale, the chief financial officer now directly owns 15,305 shares in the company, valued at $18,447,575.65. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 7.48% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on REGN shares. TD Cowen increased their target price on shares of Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the company a "buy" rating in a research report on Tuesday, July 23rd. Morgan Stanley cut their price objective on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an "overweight" rating for the company in a research report on Friday, November 1st. JPMorgan Chase & Co. decreased their target price on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an "overweight" rating on the stock in a report on Thursday, October 24th. Guggenheim raised their price target on shares of Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the company a "buy" rating in a report on Friday, August 2nd. Finally, Leerink Partners reaffirmed a "market perform" rating and issued a $1,077.00 price target (down previously from $1,175.00) on shares of Regeneron Pharmaceuticals in a report on Tuesday, September 24th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and eighteen have given a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $1,092.62.

Regeneron Pharmaceuticals Trading Up 0.5 %

Regeneron Pharmaceuticals stock traded up $3.93 during mid-day trading on Friday, reaching $828.41. 340,871 shares of the company traded hands, compared to its average volume of 521,284. The firm's 50 day moving average price is $1,035.92 and its 200 day moving average price is $1,038.36. Regeneron Pharmaceuticals, Inc. has a 52-week low of $783.57 and a 52-week high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. The firm has a market capitalization of $91.03 billion, a price-to-earnings ratio of 20.46, a P/E/G ratio of 3.12 and a beta of 0.15.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.